Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Añadir filtros

Base de datos
Tipo del documento
Intervalo de año
1.
Eur J Haematol ; 105(3): 357-359, 2020 Sep.
Artículo en Inglés | MEDLINE | ID: covidwho-108769

RESUMEN

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an inherited genetic disorder caused by red cell enzymatic defects and is associated with haemolytic crisis when patients are exposed to oxidative agents (fava beans, drugs, infections). Hydroxychloroquine is suspected to trigger haemolytic crisis in G6PD-deficient patients, and off-label administration of this drug to patients infected with the novel coronavirus (SARS-CoV-2) could cause concern. We report here the first case of severe haemolytic crisis in a patient with G6PD deficiency, initiated by severe COVID-19 infection and hydroxychloroquine use. With worldwide spread of COVID-19, especially in regions with a high prevalence of G6PD deficiency, our case should alert physicians to this possible correlation.


Asunto(s)
Betacoronavirus , Infecciones por Coronavirus/tratamiento farmacológico , Deficiencia de Glucosafosfato Deshidrogenasa/complicaciones , Hemólisis/efectos de los fármacos , Hidroxicloroquina/efectos adversos , Neumonía Viral/tratamiento farmacológico , Anciano , COVID-19 , Comorbilidad , Infecciones por Coronavirus/complicaciones , Infecciones por Coronavirus/epidemiología , Deficiencia de Glucosafosfato Deshidrogenasa/epidemiología , Humanos , Hidroxicloroquina/uso terapéutico , Masculino , Pandemias , Neumonía Viral/epidemiología , SARS-CoV-2 , Tratamiento Farmacológico de COVID-19
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA